ZL0590

CAS No. 2230496-99-6

ZL0590( —— )

Catalog No. M28525 CAS No. 2230496-99-6

ZL0590 is an effective and selective inhibitor of BD1-BRD4 (IC50 = 90 nM) with anti-inflammatory activities.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 177 In Stock
5MG 155 In Stock
10MG 235 In Stock
25MG 424 In Stock
50MG 621 In Stock
100MG 916 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    ZL0590
  • Note
    Research use only, not for human use.
  • Brief Description
    ZL0590 is an effective and selective inhibitor of BD1-BRD4 (IC50 = 90 nM) with anti-inflammatory activities.
  • Description
    ZL0590 is an effective and selective inhibitor of BD1-BRD4 (IC50 = 90 nM) with anti-inflammatory activities.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Chromatin/Epigenetic
  • Target
    Epigenetic Reader Domain
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2230496-99-6
  • Formula Weight
    512.55
  • Molecular Formula
    C23H27F3N4O4S
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (195.10 mM)
  • SMILES
    S(=O)(=O)(N1[C@H](CN2CCOCC2)CCC1)C3=CC=C(NC(NC4=CC=C(C(F)(F)F)C=C4)=O)C=C3
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Histone Acetyltransf...

    Histone Acetyltransferase Inhibitor II is a selective and cell permeable inhibitor of p300 histone acetyltransferase(IC50 : 5 μM).with anti-acetylase activity in mammalian cells.

  • Pocenbrodib

    Pocenbrodib (FT-7051) is a potent inhibitor of the bromodomain of the CBP/p300 family with potential antitumour activity and is palatable for cancer research.

  • BRD4-BD1-IN-2

    BRD4-BD1-IN-2 is a selective and potent BRD4-BD1 inhibitor with an IC50 value of 2.51 μM, exhibiting 20-fold greater inhibitory activity against BRD4-BD1 compared to BRD4-BD2.